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Background: Inflammation of peripheral airways is implicated in the pathophysiology 26 
of severe asthma. However, contributions of peripheral airway inflammation to airway 27 
caliber/function in patients with stable asthma, including those with mild to moderate 28 
disease, remain to be confirmed.  29 
Objectives: To determine whether peripheral airway inflammation affects airway 30 
function in patients with asthma.   31 
Methods: In 70 patients with mild to severe asthma, alveolar nitric oxide (CANO(TMAD)) 32 
levels were examined as a noninvasive biomarker of peripheral airway/alveolar 33 
inflammation. CANO(TMAD) and maximal NO flux in the airway compartment, J’awNO, 34 
were estimated with a model that incorporated trumpet shaped airways and axial 35 
diffusion using exhaled NO output at different flow rates. Measures of pulmonary 36 
function were then assessed by spirometry and an impulse oscillometry system, and 37 
their bronchodilator reversibility was examined. Results: CANO(TMAD) levels were not 38 
correlated with pre- or post-bronchodilator spirometric values, but were significantly 39 
associated with pre-bronchodilator reactance at low frequency (Xrs5) (rho=-0.31, 40 
p=0.011), integrated area of low-frequency Xrs (AX) (rho=0.35, p=0.003) and negative 41 
frequency dependence of resistance (Rrs5-Rrs20) (rho=0.35, p=0.004). Furthermore, 42 
CANO(TMAD) levels were associated with bronchodilator reversibility of FEV1, FEF25-75%, 43 
Xrs5, and AX (rho=0.35, rho=0.31, rho=-0.24, rho=-0.31, respectively; p≤0.05 for all). 44 
No variables were related to J’awNO. Conclusions: Elevated CANO(TMAD), but not 45 
J’awNO, partly reflects reversible airway obstruction originating in the peripheral airway. 46 
These findings indicate the involvement of peripheral airway inflammation in 47 




AX: integrated area of low-frequency reactance  51 
BD: bronchodilator 52 
CANO: alveolar fraction of exhaled NO 53 
CANO(TMAD): alveolar fraction of exhaled NO adjusted for trumpet shaped airways and 54 
axial diffusion  55 
FEF25-75%: mid forced expiratory flow 56 
FeNO: fraction of exhaled NO 57 
FeNO50: FeNO at 50 ml/sec 58 
ICS: inhaled corticosteroids 59 
IOS: impulse oscillometry system 60 
J’awNO: bronchial NO maximal flux adjusted for trumpet shaped airways and axial 61 
diffusion 62 
NO: nitric oxide 63 
Rrs: resistance of the total respiratory system  64 
Rrs5: Rrs at 5 Hz 65 
Rrs20: Rrs at 20 Hz 66 
Xrs: reactance of the total respiratory system  67 





Asthma is a chronic inflammatory disorder involving proximal airways as well as small 72 
peripheral airways [1-4]. Nitric oxide (NO) is a well-established noninvasive biomarker 73 
of inflammation in asthmatic airways [5]. Recently, the alveolar fraction of exhaled NO 74 
(CANO) has been introduced to assess inflammation of peripheral airway/alveolar 75 
regions [6]. This variable has received renewed interest as a noninvasive tool for both 76 
adults [7] and children [8]. Although CANO is mathematically derived from NO output 77 
measured at multiple flow rates, a study by Berry and colleagues has shown a strong 78 
correlation between CANO levels and eosinophil counts in bronchoalveolar lavage fluid 79 
[9], suggesting that CANO may reflect peripheral airway/alveolar inflammation. 80 
Moreover, two trumpet models with axial diffusion have recently been developed to 81 
correct the effect of axial contamination by small airway NO diffusion on CANO [10, 11]. 82 
This new parameter, CANO(TMAD), precludes overestimating actual NO production in the 83 
alveolar region. 84 
 Peripheral airway dysfunction or the degree of air trapping is associated with 85 
recurrent exacerbations of severe asthma [12] or with disease severity [13]. Effective 86 
prevention of peripheral airway dysfunction requires an understanding of the 87 
contribution of peripheral airway inflammation to airway dysfunction. However, such a 88 
contribution has been confirmed only for severe refractory asthma [14, 15]. Because 89 
peripheral airway inflammation is not limited to patients with severe disease [1], we 90 
hypothesized that sustained inflammation in the peripheral airway or alveolar region 91 
may be linked to airway dysfunction in the general population of patients with asthma. 92 
In this study, we measured CANO(TMAD), pulmonary function and pulmonary function 93 
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reversibility in response to treatment with a bronchodilator (BD) for patients with 94 
asthma ranging from mild intermittent to severe persistent. Using an impulse 95 
oscillometry system (IOS) [16] [17], we examined negative frequency dependence and 96 




This cross-sectional study was conducted at the outpatient asthma and cough 101 
clinic of Kyoto University Hospital from January through December 2007. We 102 
examined NO levels at different flow rates (50, 100, and 200 ml/s) in 75 adults with 103 
stable asthma. The inclusion criteria were as follows: 1) a diagnosis of asthma as 104 
defined by the American Thoracic Society [18] on the basis of a history of recurrent 105 
episodes of wheezing and chest tightness with or without cough; 2) confirmation of 106 
airway hyperresponsiveness on past evaluations; 3) regular attendance at our clinic for 107 
>3 months; 4) no exacerbation of asthma during the last 4 weeks; 5) no changes in 108 
treatment during the last 4 weeks; 6) non-smokers or ex-smokers who had smoked <10 109 
pack-years but had not smoked for >1 year; 7) no evidence of other respiratory diseases 110 
on chest X-ray findings. Severity was defined according to the step classification of the 111 
2004 version of the Global Initiative for Asthma guidelines [19]. Three patients with 112 
step 2 asthma were treated with leukotriene receptor antagonists because they refused to 113 
use inhaled corticosteroids (ICS). To examine patients with persistent airway 114 
inflammation, we measured NO levels at higher flows in patients with fraction of 115 
exhaled NO (FeNO) at 50 ml/sec (FeNO50) values ≥ 25 ppb [5]. The ethics committee 116 
of our institution approved the study protocol, and written informed consent was 117 
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obtained from each participant. 118 
 119 
Measurement of NO and calculation of CANO(TMAD) and bronchial NO maximal 120 
flux 121 
NO levels were measured with a chemiluminescence analyzer (NOA 280, 122 
Sievers, Boulder, CO, USA) according to current guidelines, apart from the expiratory 123 
flow rate [20]. The analyzer was calibrated daily with gas without NO generated by 124 
exposing ambient air to NO scavengers and a standard concentration of 640 ppb NO. 125 
The lower detection limit for NO was 2 ppb. The signal output from the NO analyzer 126 
was fed to a computer data acquisition program, and concentrations were measured 127 
using a data analysis program (NOA Analysis™ Software, Sievers, Boulder, CO, USA). 128 
Seated subjects inserted a mouthpiece, inhaled orally to total lung capacity, exhaled 129 
immediately against a resistance, and maintained mouth pressure at 20 cmH2O, 130 
displayed on a pressure gauge. The steady-state NO plateau was taken as the FeNO 131 
value. By varying expiratory resistances, we measured FeNO levels at three expiratory 132 
flows of 50, 100 and 200 ml/s in that order. If an adequate NO plateau was not reached 133 
at 200 ml/s, patients were then instructed to exhale at a flow of 150 ml/s instead (n=4).  134 
CANO(TMAD) was estimated using a model recently developed by Condorelli and 135 
colleagues that incorporated trumpet shaped airways and axial diffusion [10] rather than 136 
simply assuming that the lung was comprised of two separate regions with a rigid 137 
airway compartment and a well mixed expansible compartment [6]. The equation used 138 
was the following: CANO(TMAD) = slope - intercept/740. The slope and intercept of this 139 
equation were determined from a linear regression line after plotting NO output (i.e., 140 
exhaled NO level times expiratory flow) as a function of expiratory flow. When 141 
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CANO(TMAD) values were < zero, they were assigned a value of zero. Bronchial NO 142 
maximal flux (J’awNO), a marker of inflammation in the airway compartment, was also 143 
determined by multiplying the intercept by 1.7. Because this trumpet model with axial 144 
diffusion was developed based on the assumption that NO flux from the airway tree was 145 
a constant and this simplified equation was valid at an expiratory flow rate between 100 146 
ml/s and 250 ml/s, we applied FeNO levels at 100 ml/s and 200 ml/s to obtain a linear 147 
regression line between NO output and exhalation flow. Five patients whose results had 148 
negative slopes were excluded from further analysis [10]. 149 
 150 
Pulmonary function tests 151 
After NO measurements, subjects underwent pre- and post-BD (i.e., inhalation 152 
of 200 μg salbutamol) pulmonary function testing. Respiratory impedance was 153 
measured by IOS followed by spirometric testing. Reversibility of the impedance and 154 
spirometric values was calculated by: (post-BD value minus pre-BD value)/pre-BD 155 
value.  156 
 Spirometry was performed according to the standards of the American Thoracic 157 
Society [21] using a ChestGraph HI-701 spirometer (Chest, Tokyo, Japan). FEV1 and 158 
mid forced expiratory flow (FEF25-75%) were determined.  159 
 Respiratory impedance was measured using a Jaeger MasterScreen, IOSTM 160 
(Erich Jaeger, Hoechberg Germany) that met standard recommendations [22]. The IOS 161 
is different from the classical forced oscillation technique by the use of an impulse 162 
rather than a pseudorandom noise signal and in data processing. In brief, rectangular 163 
mechanical impulses containing a continuous power spectrum ranging from 0 to 100 Hz, 164 
generated by a loudspeaker at intervals of 0.2 s, were applied to the respiratory system 165 
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through a mouthpiece during tidal breathing. The resulting pressure and flow signals 166 
were measured next to the mouthpiece, and were analyzed for amplitude and phase 167 
differences using a fast Fourier transform to determine resistance (Rrs) and reactance 168 
(Xrs) of the total respiratory system. To reduce loss of energy in the upper airways, the 169 
chin and cheeks were supported by the subjects’ hands. As proxies for peripheral airway 170 
function [16] [17] [23] [24], we used the negative frequency dependence of Rrs between 171 
5 and 20 Hz (Rrs5-Rrs20), Xrs at 5 Hz (Xrs5), and reactance area (AX) that is the 172 
integral of Xrs from 5 Hz to the resonant frequency at which Xrs crosses zero. Rrs at 20 173 
Hz (Rrs20) was used as a measure of proximal airway resistance, as oscillatory pressure 174 
components at frequencies ≥20 Hz are thought to be damped out before reaching the 175 
peripheral airways [16]. 176 
 177 
Statistical analysis 178 
Data were analyzed using GraphPad Prism 4.00 (GraphPad Software, Inc., La Jolla, CA, 179 
USA) and StatView software 5.0 (SAS Institute Inc, Cary, NC, USA). When data were 180 
normally distributed, linear regression analysis was used. Otherwise, Spearman’s rank-181 
correlation test was used. The correlation coefficient from linear regression analysis is 182 
denoted as R, whereas Spearman’s correlation coefficient is given as rho. Results are 183 
expressed as means ± SDs or medians (ranges). We considered p values of ≤ 0.05 to 184 




Patients’ characteristics 188 
The characteristics of the 70 subjects are shown in Table 1. Measures of pulmonary 189 
function and FeNO50 of the 70 subjects did not differ significantly from those of the 5 190 
patients whose slopes were negative (data not shown).  191 
 192 
Correlations between patients’ characteristics and CANO(TMAD) or bronchial flux 193 
Patients with more severe asthma showed a trend for higher J’awNO levels than those 194 
with milder disease (rho=0.23, p=0.056), but not for CANO(TMAD) levels (rho=0.17, 195 
p=0.17). The presence of atopy, rhinitis and smoking history were not associated with 196 
CANO(TMAD) or J’awNO (data not shown).   197 
 198 
Correlations of CANO(TMAD) or bronchial flux with pre- and post-BD pulmonary 199 
function measures 200 
The associations of CANO(TMAD) and J’awNO with pulmonary function measures are 201 
summarized in Table 2. Correlations of pulmonary function measures with FeNO50 that 202 
were strongly correlated with J’awNO levels (rho=0.83, p<0.0001) are also shown in this 203 
table. There was no association of CANO(TMAD) with pre-BD %FEV1, %FEF25-75%, or 204 
Rrs20. CANO(TMAD) was significantly associated with pre-BD Rrs5-Rrs20, Xrs5, and AX 205 
(Fig 1). The association between Xrs5 and CANO(TMAD) remained significant even when 206 
two obvious outliers (one with the highest Xrs5 and another with the lowest Xrs5) were 207 
excluded (rho=-0.36, p=0.003 n=68). There was no association between CANO(TMAD) and 208 
any measure of post-BD pulmonary function. J’awNO was not related to any indices of 209 
pulmonary function. 210 
 9 
Measures of pre-BD Rrs5-Rrs20, Xrs5, and AX were moderately to strongly 211 
correlated with each other (|rho| ranged between 0.75 and 0.93, p<0.0001). These 212 
measures of pre-BD IOS were correlated with pre-BD %FEV1 (|rho| ranged between 213 
0.33 and 0.40, p<0.01). 214 
 215 
Correlations between CANO(TMAD) or bronchial flux and reversibility of pulmonary 216 
function measures 217 
Reversibilities of FEV1 and FEF25-75%, as well as of Xrs5 and AX, were significantly 218 
associated with CANO(TMAD) (Table 2). J’awNO was not related to any indices of 219 
reversibility.  220 
Reversibilities of FEV1, FEF25-75% Xrs5 and AX were associated with pre-BD 221 
levels; reversibility of FEV1 was correlated with the pre-BD FEV1 level (R=-0.56, 222 
p<0.0001); for %FEF25-75%, rho=-0.25, p=0.042; for Xrs5, rho=0.48, p<0.0001; for AX, 223 





To the best of our knowledge, this is the first study to demonstrate that in adult patients 228 
with stable asthma, CANO(TMAD), but not J’awNO, is significantly associated with Rrs5-229 
Rrs20, Xrs5, and AX levels, which are thought to reflect peripheral airway function. 230 
Our novel findings are that the increase in CANO(TMAD) associates with greater 231 
reversibility of FEV1, FEF25-75%, Xrs5 and AX in response to treatment with a BD. 232 
These findings suggest that peripheral airway/alveolar inflammation may contribute to 233 
reversible airway obstruction originating in the peripheral airway.  234 
 Before the introduction of CANO(TMAD), CANO had been used as a reasonably well 235 
validated marker of inflammation of the peripheral airway/alveolar region [9]. 236 
Histological studies have suggested that peripheral airway inflammation has a similar or 237 
greater impact on disease severity than does proximal airway inflammation [1, 23, 24]. 238 
Studies examining CANO have drawn similar conclusions; CANO in refractory asthma is 239 
significantly greater than that in mild to moderate asthma [9], and patients with oral 240 
steroid-dependent asthma have higher CANO levels than patients with mild-to-moderate 241 
or severe asthma [14] [25]. In this study, J’awNO showed a trend toward increased 242 
values in patients with more severe asthma than those with milder disease. However, 243 
when CANO(TMAD) was determined using a trumpet model with axial diffusion that 244 
estimated NO concentrations exiting the respiratory bronchioles and alveolar region, 245 
CANO(TMAD) was not correlated with disease severity, which is consistent with a recent 246 
finding by Mahut et al [26]. Given that CANO is not adjusted for NO axial diffusion 247 
from conducting airways and could be more contaminated by small airway NO 248 
diffusion than CANO(TMAD), this discrepancy between previous findings with CANO and 249 
those with CANO(TMAD) in this study may indicate that small airway inflammation 250 
 11 
influences asthma severity to a greater extent than the actual alveolar inflammation. 251 
Indeed, a histological study of severe asthmatics showed that small airways with 252 
perimeters less than 6 mm were the most significantly infiltrated by inflammatory cells 253 
across the entire airway tree, from the large airways to the alveolar tissue [23].  254 
Van Veen and colleagues found significant correlations of CANO with 255 
peripheral airway obstruction, as assessed by residual volume, functional residual 256 
capacity and closing capacity [14], in patients with severe asthma. However, when 257 
patients with mild-to-moderate asthma were included, these correlations disappeared, 258 
and only a significant association between CANO and the slope of the single breath 259 
nitrogen washout curve remained. Although CANO was correlated with FEF25-75% in 260 
children with refractory asthma [15], CANO was not correlated with FEF50%, FEF25%, or 261 
residual volume in adults with asthma [25]. These studies provide little or no evidence 262 
of a link between peripheral airway inflammation and dysfunction in the population of 263 
adults with asthma.  264 
In the current study, however, CANO(TMAD) was modestly, but significantly 265 
associated with small airway reactance/capacitance (Xrs5, AX) and negative frequency 266 
dependence of airway resistance (Rrs5-Rrs20). These variables obtained by IOS, a non-267 
invasive and effort-independent tool, have been proposed as relevant and sensitive 268 
indices of peripheral airway function  [16] [17] [23] [28] [27] [28]. Previous oscillation 269 
studies have demonstrated that as peripheral resistance increases, the resistance at low 270 
frequencies increases compared to the higher frequencies, thereby resulting in greater 271 
negative frequency dependence of Rrs [16, 29]. Xrs at low frequency is also considered 272 
to reflect the capacitative properties of peripheral airways and to detect peripheral 273 
airway narrowing [30]. In our recent study of patients with asthma, Rrs5-Rrs20 and AX, 274 
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but not Rrs20, are significantly associated with residual volume [23]. Another recent 275 
long-term study of controller therapy for pediatric asthma also demonstrates that AX 276 
may be sensitive to changes in peripheral airway function [27]. The nature of these 277 
indices of IOS may support our premise that Rrs5-Rrs20, Xrs, and, particularly, AX 278 
may reflect peripheral airway function. However, as discussed below, the data should be 279 
interpreted with caution because IOS indices are indirect measures, and no associations 280 
of IOS indices with pathological changes have been demonstrated thus far.  281 
Airway variability is another feature of asthma, implying instability of the 282 
disease. Endobronchial and transbronchial biopsy studies of nocturnal asthma have 283 
demonstrated a significant contribution of peripheral airway inflammation to nocturnal 284 
decrement of pulmonary function as compared with proximal airway inflammation [31]. 285 
In studies of pediatric asthma, higher FeNO levels are associated with greater FEV1 286 
reversibility [32-34]. Tsuburai and colleagues show associations between FeNO levels 287 
and FEV1 reversibility in adult asthmatics with airflow limitation, but not in those 288 
without airflow limitation [35]. Our study of adult asthmatics extended the previous 289 
findings by showing that smoldering inflammation in the peripheral airway/alveolar 290 
compartment is responsible for greater BD response in FEV1, FEF25-75%, Xrs5, and AX, 291 
and that reversibility to a BD depends on the degree of pre-BD obstruction. Given that 292 
CANO(TMAD) was correlated with pre-BD Xrs5 and AX, but not with FEV1 or FEF25-75% 293 
values, we speculate that peripheral airway/alveolar inflammation may contribute to 294 
reversible airway obstruction originating in the peripheral airway.  295 
In sharp contrast to CANO(TMAD), bronchial NO flux (i.e. J’awNO levels) was not 296 
correlated with any indices of pulmonary function and FeNO50 was only correlated with 297 
reversibility of Xrs5, which was consistent with other studies [7] [36]. This discrepancy 298 
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between CANO(TMAD) and J’awNO could be attributed to differences in their responses to 299 
ICS treatment. When patients are treated with an ICS, J’awNO readily decreases, 300 
whereas CANO is resistant to them [37]. Therefore, we speculate that any correlation of 301 
J’awNO or FeNO50 with pulmonary function might have been modified by ICS treatment. 302 
Indeed, in steroid naïve patients, exhaled NO levels are correlated with airway 303 
hyperresponsiveness [38], asthma symptom scores [39], or with bronchodilator response 304 
[34], whereas such correlations disappear in patients on ICS. Intriguingly, a recent study 305 
shows significant associations between exhaled NO levels and FEV1 or bronchodilator 306 
responses in pediatric asthmatics receiving ICS treatments when they are classified 307 
according to their ICS doses [40], which may suggest that stratifying patients by ICS 308 
doses could provide deeper insights into the roles of exhaled NO in patients on ICS. 309 
The role of CANO(TMAD) in peripheral airway obstruction should not be 310 
overestimated because the associations were modest; elevated CANO(TMAD) is not a 311 
strong indicator for low Xrs5 or increased AX. Also, IOS variables were not compared 312 
with closing volume or closing capacity, other proxy measures of peripheral airway 313 
obstruction. As mentioned above, IOS measurements have several limitations and 314 
should be interpreted cautiously [16] [17] because of issues that include artifact effects 315 
of upper airway compliance and leaks at the mouthpiece. Increases in Rrs5-Rrs20 may 316 
imply heterogeneity of peripheral airway narrowing in addition to an absolute increase 317 
in resistance [41]. Xrs5 is relatively noise-sensitive, whereas AX is less so. Resistance 318 
and reactance in the peripheral airway may indicate different properties, given that pre-319 
BD values of Rrs5-Rrs20 were not correlated with reversibility to a BD, whereas pre-320 
BD values of AX and Xrs5 were, although precise mechanisms underlying this 321 
discrepancy are unknown.  322 
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We may have missed some patients with normal FeNO50 and high CANO(TMAD) 323 
by excluding those with FeNO50 < 25 ppb. When pediatric patients with asthma are 324 
grouped based on their J’awNO and CANO(TMAD) levels, Puckett et al find that 11% of the 325 
patients have normal J’awNO and high CANO(TMAD) levels [42]. However, when we 326 
examined another 21 patients with stable asthma who had FeNO50 < 25 ppb, their ratios 327 
of CANO(TMAD) levels to FeNO50 levels did not differ from those of the currently studied 328 
population (data not shown), suggesting that patients with normal FeNO50 and high 329 
CANO(TMAD) are not commonly observed in our patient population. Therefore, we believe 330 
that the possibility of missing patients with normal FeNO50 and high CANO(TMAD) may 331 
not have severely affected our findings.  332 
Five patients were excluded from the analysis because their results had 333 
negative slopes in plots of NO output vs. expiratory flow between 100 ml/s and 200 334 
ml/s. NO axial diffusion from the airway tree increases as bronchial flux increases and 335 
its relative impact over NO conductive transport exiting the alveolar region is greater at 336 
lower expiratory flows [10]. Therefore, the negative slopes for five patients may 337 
indicate that, in these patients, the relative impact of NO axial diffusion on NO output 338 
with exhalation flows around 100 ml/s might have remained either because of increased 339 
bronchial reflux or because of relatively small NO production in the alveolar region. 340 
Measurements with higher expiratory flows would have been desirable, but it was 341 
difficult for our patients to obtain a steady-state NO plateau with higher flows, such as 342 
at 250 ml/s or 300 ml/s. Despite these limitations, our findings support the superiority of 343 
a multiple flow technique to a conventional single flow measurement, as the former 344 
provides information on peripheral airway/alveolar inflammation.  345 
In conclusion, inflammation in the peripheral airway/alveolar region as 346 
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assessed by CANO(TMAD) partly contributes to the development of peripheral airway 347 
obstruction and to reversibility of pulmonary function in response to a bronchodilator. 348 
Monitoring peripheral airway/alveolar inflammation may provide higher-quality 349 
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Figure legend 485 
Figure 1. Relationships between CANO(TMAD) levels and pre-bronchodilator Xrs5 (left) 486 
and Rrs5-Rrs20 (right).  487 
488 
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Table 1. Patients’ characteristics (n=70) 489 
Gender, M/F 33/37  490 
Age, yr 57.4 ±15.6 491 
Disease duration, yr 12.2 ± 10.4 492 
Asthma severity*, 1/2/3/4 2/35/17/16 493 
Atopy, positive†, % 66  494 
IgE, IU 190 (5, 6800) 495 
Ex smoker, % 33  496 
Sinusitis/rhinitis, % 66  497 
Daily dose of ICS‡, µg 400 (0, 1600) 498 
%FEV1, % 89.4 ± 16.5  499 
%FEF25-75%, % 57.4 ± 26.8 500 
Rrs20, kPa·s·L-1 0.32 ± 0.11 501 
Rrs5-Rrs20, kPa·s·L-1 0.06 (-0.03, 0.43) 502 
Xrs5, kPa·s·L-1 -0.13 (-0.56, 0.17) 503 
AX, kPa·s·L-1 0.44  (0.01, 5.51) 504 
FeNO50, ppb 44.9  (25.0, 224.4) 505 
J’awNO, pl·s-1 3638 (0, 15300)  506 
CANO(TMAD), ppb 3.9 (0, 34.9)  507 
 508 
*According to the Global Initiative for Asthma guidelines [19]. †Considered atopic 509 
when one or more specific IgE antibodies against house dust mite, cat dander, dog 510 
dander, molds, weed, cedar pollen, or grass pollen were positive. ‡Equivalent dose of 511 
fluticasone. ICS = inhaled corticosteroids, Rrs20 = resistance of the total respiratory 512 
system at 20 Hz, Rrs5 = Rrs at 5 Hz, Xrs5 = reactance at 5 Hz, AX = area of low-513 
frequency reactance, FeNO50 = exhaled NO level at flow of 50 ml/s, J’awNO = bronchial 514 
NO maximal flux adjusted for trumpet shaped airways and axial diffusion, CANO(TMAD) 515 
= alveolar fraction of exhaled NO adjusted for trumpet shaped airways and axial 516 
diffusion 517 
Values are means ± SD or median (range).  518 
519 
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Table 2. Correlation coefficients of NO levels with pulmonary function values 520 
  CANO(TMAD) J’awNO  FeNO50 521 
Pre-bronchodilator 522 
 %FEV1 -0.18 -0.03 -0.12 523 
 %FEF25-75% -0.09 -0.05 -0.10 524 
Rrs20 0.22 -0.17 -0.05  525 
 Rrs5-Rrs20 0.35† -0.09 0.11 526 
 Xrs5 -0.31* -0.05 -0.19 527 
 AX 0.35† -0.03 0.14 528 
Reversibility 529 
 ∆FEV1 0.35† -0.007 0.09 530 
 ∆FEF25-75% 0.31* 0.09 0.21 531 
 ∆Rrs20 -0.23 -0.007 -0.01 532 
 ∆(Rrs5-Rrs20) -0.22 0.05 0.01 533 
 ∆Xrs5 -0.24* -0.16 -0.25* 534 
 ∆AX -0.31* -0.16 -0.10 535 
*: p ≤ 0.05, †: p < 0.01, Correlation coefficients of Spearman’s correlation coefficients 536 
are shown. 537 
∆ = (post-bronchodilator value minus pre-bronchodilator value) / pre-bronchodilator 538 
value, Rrs20 = resistance of the total respiratory system at 20 Hz, Rrs5 = Rrs at 5 Hz 539 
Xrs5 = reactance at 5 Hz, AX = integrated area of low-frequency reactance,  540 
CANO(TMAD) = alveolar fraction of exhaled NO adjusted for trumpet shaped airways and 541 
axial diffusion, J’awNO = bronchial NO maximal flux adjusted for trumpet shaped 542 
airways and axial diffusion, FeNO50 = fraction of exhaled NO at 50 ml/sec 543 
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